Views & Analysis 5 years of biosimilars in the US: what have we learned? Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide.
Views & Analysis Who could replace Sir Andrew Dillon at NICE? With Sir Andrew Dillon announcing his retirement as chief executive of NICE, pharmaphorum discusses potential replacements for the man who is arguably the most influential figure in health
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.